# Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort

> **NCT02516592** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 500 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** QVA149 110/50 micrograms
- **DRUG:** Salmeterol/fluticasone 50/500 microgrammes

## Key facts

- **NCT ID:** NCT02516592
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-13
- **Primary completion:** 2017-05-04
- **Final completion:** 2017-05-04
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02516592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02516592, "Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02516592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*